Aplastic Anaemia Pipeline Analysis report covers 8 drugs currently in different phases of development. Aplastic Anaemia is a rare, serious condition which occurs when bone marrow fails to produce enough new cells. Symptoms of aplastic anaemia are fatigue, breathlessness or shortness of breath, irregular or rapid heartbeat, frequent bleeding from nose and gums, prolonged or uncontrolled bleeding from cuts and wounds, skin rash, dizziness and headache. Aplastic anaemia occurs as a result of damage to the bone marrow due to radiation or chemotherapy treatments, exposure to toxic chemicals, certain autoimmune disorders or various other factors. Diagnosis is done by blood tests and bone marrow biopsy. Preferred treatment options for aplastic anemia are blood transfusions and bone marrow transplant.
The report provides Aplastic Anaemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are, Hemogenyx Pharmaceuticals PLC, Amgen and Pluristem Therapeutics Inc. among others.
By Molecule Type
By Route of Administration